Key Drivers
- High Margins
- Strong Liquidity
- Rich Valuation
AIAI Summary
LMAT remains financially strong with high margins, low leverage, and solid demand, but after the Q2 miss and guidance cut the stock is now a “show me” name where near-term upside depends on resolving FX, export delays, and tissue supply constraints fast enough to justify a still-rich valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High Margins
- •Strong Liquidity
- •Rich Valuation
LeMaitre Vascular has strong profitability, low leverage, and excellent liquidity/cash generation, but its elevated valuation leaves limited near-term upside.
Price Behavior
Key Price Behavior Insights:
- •Trend reversal
- •Low-$80s base
- •Overhead supply
LMAT has turned from an uptrend into a downtrend over the last month after a sharp break in early August, but basing in the low $80s shows some defense at $79-$81 unless it can reclaim $95-$100.
Sharp break on 2026-08-05 after trading in the low $100s in late
Sentiment & News
Key News Insights:
- •Organic growth
- •Margin strength
- •Supply constraints
LeMaitre Vascular posted strong 10% organic growth and record operating income, but earnings and a modest guidance cut disappointed as currency, export delays, and tissue shortages pressured results rather than underlying demand.
The stock may stay volatile near term, but the core growth story remains intact if temporary supply and FX headwinds ease
Similar Companies in Healthcare
Other companies in the same sector with AI ratings